American biopharmaceutical company propels COVID-19 trial recruitment with AI/ML-based geofenced targeting

2 Pages

An American biopharmaceutical company with an immunology and immuno-oncology portfolio accelerated COVID-19 trial recruitment for its Phase 3 LIVE-AIR study treating cytokine storm in hospitalized patients, aiming to boost participants from 300 to 520. Challenges included tight timelines, sifting relevant patients from generic website traffic, and US election-related promotion limits. Indegene's AI/ML-powered software delivered geofenced targeting to precisely identify and engage eligible participants, streamlining recruitment, overcoming restrictions, and rapidly scaling enrollment for trial success.

Join for free to read

White Paper COVID-19 TECHNOLOGY AND SERVICES SOLUTIONS GUIDE

Case Study The Impact of Covid-19 on North American Grocery Retailers

Case Study LifeSphere vs. COVID-19

Ebook What do COVID-19 Vaccine Timelines Mean For Clinical…

More from Indegene

Case Study Indegene accelerates patient recruitment for a global biopharma…

Case Study Indegene’s MarTech expertise helps a leading biopharmaceutical…

Case Study Global Pharma Partners with Indegene for Clinical Trial…

Case Study Indegene ensures compliance with clinical trial submission…

Case Study

American biopharmaceutical company propels COVID-19 trial recruitment with AI/ML-based geofenced targeting

American biopharmaceutical company propels COVID-19 trial recruitment with AI/ML-based geofenced targeting

You Might Also Like

More from Indegene